AnaptysBio (ANAB) Earnings Call Presentation

Rosnilimab Phase 2b RA Trial Key Findings - Rosnilimab demonstrates a best-in-disease profile in RA through 6 months[8, 95] - Max response rates have not yet been observed, indicating potential for further improvement[9, 96] - Responses are durable after 6 months, suggesting potential for extended dosing intervals[10, 97] - The trial included 424 randomized patients in a placebo-controlled Phase 2b study[7, 17] - 95% of trial participants had high disease activity at baseline[18] - 95% completed the 6-month all-active treatment period, supporting favorable efficacy and tolerability[20] Efficacy and Safety Comparisons - Rosnilimab shows JAK-like efficacy in naïve patients[11] - ACR20 response rates are comparable to Rinvoq[23] - Rosnilimab surpassed the Target Product Profile (TPP) in experienced patients and is comparable to JAKs in all-active head-to-head studies[14, 58] - Rosnilimab is well-tolerated with a low dropout rate due to adverse events[81]